"Heredity accounts for up to 35 percent of small intestinal carcinoid, a rare digestive cancer, according to findings from a team at the National Institutes of Health. The researchers examined families with a history of the disease. Because the"...
The maximum amount of LEUKINE (sargramostim) that can be safely administered in single or multiple doses has not been determined. Doses up to 100 mcg/kg/day (4,000 mcg/m²/day or 16 times the recommended dose) were administered to four patients in a Phase I uncontrolled clinical study by continuous IV infusion for 7 to 18 days. Increases in WBC up to 200,000 cells/mm³ were observed. Adverse events reported were dyspnea, malaise, nausea, fever, rash, sinus tachycardia, headache and chills. All these events were reversible after discontinuation of LEUKINE (sargramostim) .
In case of overdosage, LEUKINE (sargramostim) therapy should be discontinued and the patient carefully monitored for WBC increase and respiratory symptoms.
LEUKINE (sargramostim) is contraindicated:
- in patients with excessive leukemic myeloid blasts in the bone marrow or peripheral blood ( ≥ 10%);
- in patients with known hypersensitivity to GM-CSF, yeast derived products or any component of the product;
- for concomitant use with chemotherapy and radiotherapy.
Due to the potential sensitivity of rapidly dividing hematopoietic progenitor cells, LEUKINE (sargramostim) should not be administered simultaneously with cytotoxic chemotherapy or radiotherapy or within 24 hours preceding or following chemotherapy or radiotherapy. In one controlled study, patients with small cell lung cancer received LEUKINE (sargramostim) and concurrent thoracic radiotherapy and chemotherapy or the identical radiotherapy and chemotherapy without LEUKINE (sargramostim) . The patients randomized to LEUKINE (sargramostim) had significantly higher incidence of adverse events, including higher mortality and a higher incidence of grade 3 and 4 infections and grade 3 and 4 thrombocytopenia.11
11. Bunn P, Crowley J, Kelly K, et al. Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the southwest oncology group. JCO 1995; 13(7):1632-1641.This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 8/12/2008
Additional Leukine Information
Leukine - User Reviews
Leukine User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.